Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of zolbetuximab + pembrolizumab + chemotherapy as first-line treatment for HER2-negative, CLDN18.2-positive, PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20253090Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Nov 2025; status: active.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20253090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253090.